advent
publicli
avail
databas
contain
systemwid
phenotyp
data
host
respons
drug
pathogen
conjunct
bioinformat
comput
method
allow
silico
predict
fdaapprov
drug
treatment
infect
diseas
system
biolog
approach
captur
complex
pathogen
drug
host
respons
form
express
pattern
molecular
interact
network
without
understand
underli
mechan
action
drug
repurpos
techniqu
success
identifi
new
drug
candid
sever
type
cancer
recent
use
identifi
potenti
therapeut
influenza
newli
discov
middl
eastern
respiratori
syndrom
coronaviru
sever
parasit
diseas
new
approach
potenti
significantli
reduc
time
cost
infecti
diseas
drug
discoveri
drug
develop
research
infecti
diseas
led
number
effect
therapi
centuri
howev
still
mani
diseas
drug
vaccin
avail
diseas
caus
influenza
viru
hepat
c
viru
treatment
suboptim
effect
subset
popul
reductionist
structurebas
drug
design
effort
reli
de
novo
predict
select
set
small
molecul
compound
interact
target
pathogen
host
protein
predict
typic
difficult
time
consum
costli
addit
approach
need
discov
new
treatment
improv
exist
one
one
promis
approach
drug
repurpos
reposit
appli
known
drug
compound
new
indic
although
idea
new
past
techniqu
reli
hypothesisdriven
approach
usual
involv
comput
match
compound
specif
viral
human
protein
requir
larg
amount
expert
knowledg
chemic
compound
drug
target
studi
recent
develop
open
door
use
drug
repurpos
approach
reli
gener
empir
data
relat
bind
characterist
mechan
action
instead
approach
use
method
system
biolog
bioinformat
directli
compar
host
respons
pathogen
drug
comput
method
use
paradigm
vari
complex
genom
signatur
comparison
complic
interact
network
combin
systemat
databas
druginduc
gene
express
profil
method
util
data
varieti
highthroughput
techniqu
eg
transcriptom
proteom
metabolom
thu
allow
identif
potenti
host
drug
target
globalscal
figur
significantli
reduc
timefram
predict
host
molecul
effect
therapeut
intervent
compound
typic
previous
fdaapprov
drug
small
molecul
approach
potenti
greatli
reduc
time
cost
associ
drug
develop
importantli
alreadi
success
applic
approach
sever
diseas
indic
time
therefor
hand
infecti
diseas
field
embrac
new
paradigm
effort
improv
effect
drug
discoveri
illustr
immedi
access
potenti
approach
discuss
exampl
outsid
infecti
diseas
field
reli
systemswid
host
respons
dataset
publicli
avail
dataset
known
drug
small
molecul
comput
approach
use
predict
potenti
effect
diseasedrug
combin
simplest
term
invers
genom
signatur
approach
base
premis
effect
drug
gener
gene
express
profil
invers
correl
host
signatur
associ
diseas
approach
incorpor
complex
genomewid
respons
host
diseas
treatment
root
scalar
theori
mrna
express
profil
contain
inform
associ
higherlevel
protein
interact
concord
either
diseas
drug
treatment
exampl
approach
use
connect
map
cmap
public
databas
http
wwwbroadinstituteorg
cmap
version
hold
transcriptom
profil
establish
downstream
treatment
human
cell
line
compound
fdaapprov
drug
addit
transcriptom
profil
cmap
resourc
provid
analyt
tool
among
thing
calcul
connect
score
score
measur
invers
similar
neg
correl
signatur
exampl
dudley
et
al
use
method
identifi
new
therapeut
agent
inflammatori
bowel
diseas
ibd
progress
inflammatori
disord
known
cure
current
treatment
sever
side
effect
expens
ineffect
mani
individu
studi
modifi
version
comput
methodolog
develop
lamb
et
al
use
compar
compendium
known
drug
compound
cmap
ibdspecif
gene
express
signatur
deriv
dataset
avail
gene
express
omnibu
geo
two
strongest
anticorrel
treatment
signatur
prednisolon
wellknown
treatment
crohn
diseas
major
type
ibd
topiram
anticonvuls
drug
use
treat
epilepsi
use
rodent
model
ibd
shown
topiram
significantli
reduc
gross
patholog
microscop
damag
affect
colon
compar
seen
control
anim
importantli
topiram
side
effect
treatment
neurolog
symptom
human
sever
current
ibd
treatment
drug
repurpos
infecti
diseas
drug
discoveri
law
et
al
host
respons
compon
drug
repurpos
paradigm
systemwid
phenotyp
dataset
mrna
express
proteom
metabolom
collect
character
host
respons
drug
pathogen
submit
public
repositori
allow
data
integr
comparison
use
varieti
bioinformat
comput
method
includ
invers
genom
signatur
networkbas
approach
analys
result
drug
repurpos
predict
identifi
potenti
effect
fdaapprov
drug
therapeut
correspond
infect
diseas
one
first
applic
approach
infecti
diseas
josset
et
al
use
host
transcript
respons
influenza
viru
queri
cmap
databas
major
current
antivir
drug
target
specif
viral
protein
make
narrow
spectrum
vulner
emerg
viral
resist
josset
cowork
reason
treat
viru
infect
stimul
manipul
innat
immun
respons
target
cellular
factor
requir
viral
life
cycl
would
prove
advantag
tradit
approach
target
viral
protein
common
gene
express
signatur
consist
dysregul
gene
identifi
human
lung
epitheli
cell
infect
human
avian
influenza
viru
cmap
databas
queri
identifi
candid
compound
genom
signatur
invers
correl
common
influenza
virusinduc
host
transcriptom
profil
eight
candid
drug
identifi
major
approv
indic
six
drug
inhibit
viral
growth
vitro
assay
importantli
five
eight
also
inhibit
growth
pandem
influenza
viru
use
defin
common
signatur
approach
therefor
potenti
identifi
drug
effect
spectrum
relat
virus
addit
excit
aspect
invers
genom
signatur
approach
abil
rapidli
identifi
potenti
drug
emerg
infecti
diseas
demonstr
recent
studi
laboratori
determin
host
respons
newli
discov
middl
eastern
respiratori
syndrom
coronaviru
merscov
merscov
first
identifi
saudi
arabia
septemb
sinc
caus
least
confirm
infect
result
death
use
human
cell
cell
line
deriv
epitheli
cell
line
human
conduct
airway
global
transcript
profil
host
respons
signatur
earli
host
respons
identifi
use
signatur
two
independ
bioinformat
tool
cmap
connect
score
ipa
upstream
regul
analysi
ingenu
system
wwwingenuitycom
two
kinas
inhibitor
identifi
potenti
antimerscov
treatment
valid
top
predict
neg
regul
cell
treat
merscov
infect
result
signific
reduct
viral
titer
hour
post
infect
studi
demonstr
potenti
silico
approach
predict
drug
candid
vitro
efficaci
merscov
wherea
studi
describ
focus
use
gene
express
pattern
also
possibl
take
advantag
deeper
understand
host
respons
come
network
model
biomolecular
network
connect
molecular
compon
gene
protein
metabolit
specif
type
interact
use
repres
function
relationship
among
variou
compon
network
function
relationship
physic
chemic
interact
genet
regulatori
interact
associ
network
may
construct
captur
variou
scale
rang
molecular
cellular
level
tissu
organism
level
network
dynam
analyz
provid
inform
complex
diseas
infer
novel
relationship
reveal
emerg
properti
biolog
system
applic
system
biolog
infecti
diseas
research
increasingli
use
identifi
host
target
antimicrobi
therapeut
predict
novel
pathogen
virul
factor
wealth
function
genom
data
publicli
avail
network
pharmacolog
begin
make
inroad
infecti
diseas
research
although
indepth
review
networkbas
approach
drug
repurpos
beyond
scope
articl
sever
recent
review
focus
complex
human
diseas
network
tool
analyz
network
topolog
dynam
network
drug
combin
discuss
recent
studi
use
networkbas
approach
target
identif
drug
discoveri
identifi
novel
gene
drug
target
barrena
et
al
built
upon
knowledg
gene
contain
diseaseassoci
snp
tend
form
highli
connect
cluster
proteinprotein
interact
network
gene
differenti
express
complex
diseas
inform
use
identifi
highli
interconnect
gene
cluster
coresuscept
modul
highli
divers
complex
diseas
done
construct
individu
diseasespecif
network
use
global
human
proteinprotein
interact
network
gene
express
dataset
diseas
highli
interconnect
cluster
overlap
diseas
network
determin
use
permut
test
reveal
signific
level
snp
enrich
obtain
coresuscept
modul
compar
whole
proteinprotein
interact
network
test
correl
coresuscept
modul
snp
could
identifi
novel
host
drug
target
novel
gene
associ
diseas
suscept
network
construct
analysi
repeat
use
gene
express
snp
dataset
anoth
complex
diseas
season
allerg
rhiniti
sar
ie
hay
fever
analysi
identifi
two
novel
sarassoci
gene
fibroblast
growth
factor
mitogenactiv
protein
kinas
latter
known
play
role
type
allerg
inflamm
potenti
function
relev
drug
target
confirm
knock
polar
cell
result
dysregul
gene
involv
type
allerg
inflamm
drug
repurpos
strategi
may
also
valuabl
find
therapeut
rare
diseas
littl
financi
incent
drug
develop
exampl
mei
et
al
use
multiplelevel
network
model
mlnm
approach
identifi
drug
treat
rare
central
nervou
system
cn
diseas
use
publicli
avail
diseasegen
express
profil
pathophysiolog
pathway
analysi
inform
fdaapprov
drug
latestag
compound
integr
cn
diseas
network
construct
diseas
link
relationship
degre
commonli
share
pathway
express
pattern
respons
drug
compound
use
robust
associ
statist
cutoff
hierarch
cluster
hypothesi
similar
diseas
caus
dysregul
relat
pathway
sever
potenti
drug
identifi
exampl
result
predict
parkinson
diseas
drug
could
effect
repurpos
therapi
basal
ganglia
diseas
similarli
approach
show
multipl
sclerosi
ms
neuromyel
optica
autoimmun
disord
consist
simultan
inflamm
demyelin
optic
nerv
spinal
cord
share
common
mechanist
pathway
suggest
ms
drug
could
effect
diseas
novel
approach
daminelli
et
al
use
offtarget
effect
known
promiscu
drug
advantag
networkbas
strategi
integr
publicli
avail
drugtarget
drugdiseas
interact
use
result
integr
drugtargetdiseas
network
new
link
drug
target
diseas
identifi
evalu
exampl
quercetin
bioflavonoid
antiinflammatori
antioxid
properti
resveratrol
polyphenol
compound
found
red
wine
specul
explain
french
paradox
predict
bind
two
target
known
bind
partner
quercetin
resveratrol
respect
potenti
effect
neoplasm
cardiovascular
diseas
literatur
search
reveal
quercetin
bind
recent
verifi
use
vitro
pulldown
assay
although
resveratrol
appear
bind
directli
inhibit
phosphoryl
report
antitumor
activ
drug
repurpos
approach
therefor
show
promis
identifi
drug
treat
varieti
diseas
includ
infecti
diseas
howev
also
caveat
awar
step
taken
ensur
approach
bear
fruit
instanc
publicli
avail
drug
profil
obtain
use
cell
line
model
system
mean
inform
relat
intercellular
mechan
captur
addit
public
fund
need
extens
databas
expand
number
drug
profil
model
system
use
equal
import
avail
dataset
host
respons
infecti
diseas
end
nation
institut
allergi
infecti
diseas
niaid
sponsor
five
system
biolog
center
infecti
diseas
research
center
focu
model
host
respons
pathogen
influenza
viru
sarscov
mycobacterium
tuberculosi
salmonella
typhimurium
yersinia
pesti
recent
malaria
parasit
result
hostrespons
dataset
along
signific
amount
metadata
captur
niaid
bioinformat
resourc
center
therebi
allow
investig
use
extens
systemat
obtain
genom
proteom
metabolom
dataset
comput
studi
also
current
limit
comput
tool
use
integr
drug
hostrespons
profil
exist
patternmatch
techniqu
use
prior
knowledg
form
gene
ontolog
function
annot
databas
gokegg
ingenu
pathway
analysi
limit
searchabl
pattern
alreadi
known
pathway
addit
cmap
search
simpl
short
differenti
express
gene
list
rather
complex
dataset
obtain
use
multipl
biolog
condit
cover
human
gene
result
greater
bia
lower
throughput
addit
method
need
develop
overcom
limit
cours
potenti
drug
identifi
approach
step
must
still
taken
valid
clinic
efficaci
review
highlight
use
mrna
proteom
profil
howev
systemwid
metric
could
potenti
use
includ
profil
microrna
long
noncod
rna
epigenet
modif
recent
us
suprem
court
decis
ban
patent
human
gene
hard
imagin
soon
individu
genet
makeup
person
genom
diseas
signatur
screen
drug
databas
tailor
person
medic
treatment
final
identifi
compound
alreadi
evalu
human
subject
drug
repurpos
approach
may
particular
benefit
identifi
treatment
employ
rare
emerg
infecti
diseas
adjunct
common
approach
highthroughput
screen
structurebas
drug
design
comput
drug
repurpos
potenti
rapidli
translat
insight
gain
system
biolog
drug
discoveri
strategi
directli
applic
treatment
infecti
diseas
